PL2594587T3 - Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry - Google Patents
Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostryInfo
- Publication number
- PL2594587T3 PL2594587T3 PL12193118T PL12193118T PL2594587T3 PL 2594587 T3 PL2594587 T3 PL 2594587T3 PL 12193118 T PL12193118 T PL 12193118T PL 12193118 T PL12193118 T PL 12193118T PL 2594587 T3 PL2594587 T3 PL 2594587T3
- Authority
- PL
- Poland
- Prior art keywords
- adm
- antibody
- acute
- adrenomedullin
- mortality
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189450 | 2011-11-16 | ||
| EP12160017 | 2012-03-16 | ||
| EP12193118.2A EP2594587B1 (en) | 2011-11-16 | 2012-11-16 | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2594587T3 true PL2594587T3 (pl) | 2014-11-28 |
Family
ID=48087102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12193118T PL2594587T3 (pl) | 2011-11-16 | 2012-11-16 | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2594587B1 (pl) |
| JP (1) | JP6321544B2 (pl) |
| AU (1) | AU2012338730B2 (pl) |
| CA (1) | CA2856136A1 (pl) |
| DK (1) | DK2594587T3 (pl) |
| ES (1) | ES2494190T3 (pl) |
| PL (1) | PL2594587T3 (pl) |
| PT (1) | PT2594587E (pl) |
| SG (1) | SG11201402362VA (pl) |
| WO (1) | WO2013072510A1 (pl) |
| ZA (1) | ZA201403551B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339324A1 (en) * | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| MX2019007107A (es) * | 2016-12-16 | 2019-10-21 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. |
| WO2018216580A1 (ja) * | 2017-05-22 | 2018-11-29 | 東ソー株式会社 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 |
| EP3682246A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Method for guidance of fluid therapy based on proadrenomedullin |
| WO2019057992A2 (en) * | 2017-09-25 | 2019-03-28 | Adrenomed Ag | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
| BR112020005682A2 (pt) | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
| WO2021099600A1 (en) | 2019-11-22 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| AU2021228207A1 (en) | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
| CA3168978A1 (en) * | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2021170880A2 (en) | 2020-02-27 | 2021-09-02 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| EP4121772A1 (en) | 2020-03-16 | 2023-01-25 | sphingotec GmbH | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| WO2022177018A1 (ja) * | 2021-02-22 | 2022-08-25 | 国立大学法人宮崎大学 | 長時間作用型アドレノメデュリン誘導体の製造方法 |
| CN116355860A (zh) * | 2021-12-28 | 2023-06-30 | 四川远大蜀阳药业有限责任公司 | 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用 |
| CN119072492A (zh) | 2022-03-15 | 2024-12-03 | 艾德里诺医药公司 | 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 |
| IL318667A (en) | 2022-07-29 | 2025-03-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| EP4562430A1 (en) | 2022-07-29 | 2025-06-04 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2005508623A (ja) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | 改変されたトランスフェリン融合タンパク質 |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| JP2007523844A (ja) | 2003-04-25 | 2007-08-23 | ジェノバ・リミテッド | 心臓血管障害において減少する分泌ポリペプチド種 |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| EP1800131A2 (en) | 2004-09-09 | 2007-06-27 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
| WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| EP2358746B1 (en) | 2008-11-03 | 2020-09-16 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| RU2550272C2 (ru) | 2009-08-27 | 2015-05-10 | Коваген Аг | Новые il-17-связывающие соединения и их медицинское применение |
| RU2556820C2 (ru) | 2009-12-14 | 2015-07-20 | Сцил Протеинс Гмбх | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина |
| DE102010040035A1 (de) | 2010-03-04 | 2011-09-08 | Robert Bosch Gmbh | Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren |
| US8986951B2 (en) | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
-
2012
- 2012-11-16 PL PL12193118T patent/PL2594587T3/pl unknown
- 2012-11-16 DK DK12193118.2T patent/DK2594587T3/da active
- 2012-11-16 ES ES12193118.2T patent/ES2494190T3/es active Active
- 2012-11-16 WO PCT/EP2012/072929 patent/WO2013072510A1/en not_active Ceased
- 2012-11-16 PT PT121931182T patent/PT2594587E/pt unknown
- 2012-11-16 EP EP12193118.2A patent/EP2594587B1/en active Active
- 2012-11-16 SG SG11201402362VA patent/SG11201402362VA/en unknown
- 2012-11-16 JP JP2014541694A patent/JP6321544B2/ja active Active
- 2012-11-16 AU AU2012338730A patent/AU2012338730B2/en active Active
- 2012-11-16 CA CA2856136A patent/CA2856136A1/en active Pending
-
2014
- 2014-05-15 ZA ZA2014/03551A patent/ZA201403551B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2594587B1 (en) | 2014-05-21 |
| WO2013072510A1 (en) | 2013-05-23 |
| ES2494190T3 (es) | 2014-09-15 |
| CA2856136A1 (en) | 2013-05-23 |
| AU2012338730B2 (en) | 2017-07-06 |
| SG11201402362VA (en) | 2014-06-27 |
| ZA201403551B (en) | 2015-01-28 |
| EP2594587A1 (en) | 2013-05-22 |
| DK2594587T3 (da) | 2014-07-21 |
| PT2594587E (pt) | 2014-08-27 |
| JP6321544B2 (ja) | 2018-05-09 |
| NZ624869A (en) | 2016-06-24 |
| JP2015502930A (ja) | 2015-01-29 |
| AU2012338730A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2594587T3 (pl) | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry | |
| ZA201906427B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| ZA201403550B (en) | Anti-adrenomedullin (adm) antibody of anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease | |
| ZA201403549B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| PL2594588T3 (pl) | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii | |
| IL274686B (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| DK2713935T3 (da) | Kirurgisk afdækning med adskillelige elementer | |
| EP2672942A4 (en) | PILOT TOWER FOR A WHEELCHAIR | |
| LT2768859T (lt) | Il17c antagonistai, skirti uždegiminių ligų gydymui | |
| FI20115180L (fi) | Koostumus käytettäväksi sairauden hoidossa | |
| PL2928461T3 (pl) | Leczenie przewlekłej choroby nerek |